Up to one-third of all patients admitted to intensive care units carry a diagnosis of shock. The use of angiotensin II is becoming widespread in all forms of shock, including cardiogenic, after the U.S. Food and Drug Administration's (FDA's) initial approval for vasoplegic shock in 2017. Here, the authors review the literature on angiotensin II's mechanism of action, benefits, and future therapeutic opportunities.
Keywords: angiotensin II; cardiogenic shock; pressor; shock; vasoplegia; vasoplegic shock.
Copyright © 2021 Elsevier Inc. All rights reserved.